Foundation Medicine, Inc. (FMI): Michael J Pellini , Chief Executive Officer of Foundation Medicine, Inc. sold 10,160 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $17.83 per share for a total value of $179,092.72 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 6, 2016, Vincent A. Miller (Chief Medical Officer) sold 4,828 shares at $17.68 per share price.On Jul 6, 2016, Steven J. Kafka (President & COO) sold 6,495 shares at $17.68 per share price.Also, On Jul 6, 2016, Robert W. Hesslein (SVP and General Counsel) sold 4,705 shares at $17.83 per share price.On Jun 7, 2016, David Daly (Chief Commercial Officer) sold 472 shares at $21.66 per share price.
Foundation Medicine Inc: On Tuesday, Jul 6, 2016 heightened volatility was witnessed in Foundation Medicine Inc which led to swings in the share price. The shares opened for trading at $18.26 and hit $20.74 on the upside , eventually ending the session at $20.29, with a gain of 6.62% or 1.26 points. The heightened volatility saw the trading volume jump to 7,56,611 shares. The 52-week high of the share price is $34.18 and the company has a market cap of $702 M . The 52-week low of the share price is at $13.34.
Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.